Point Roberts, WA - March 6 2013 (Investorideas.com Newswire)
Investorideas.com staff: Investorideas.com, an investor research portal
specializing in sector research for independent investors issues a
trading alert for microcap biotech stock, Bio-Matrix Scientific Group
Inc. (OTC : BMSN ), currently trading at $0.0144, up 0.0010(7.46%) as of 10:11AM EST. The stock had a morning high of 0.0155.
Investorideas.com reported on the stock breaking previous trading
patterns on February 15 th, noting a technical breakout. The stock
pulled back and settled into another trading range that broke out in the
past two days.
On February 5 th, Regen BioPharma a wholly-owned subsidiary of Bio-Matrix Scientific Group Inc. (OTC : BMSN
), announced filing of an Investigational New Drug (IND) application
with the FDA to initiate clinical trials assessing the company's
HemaXellerate I™ stem cell drug in patients with drug-refractory
aplastic anemia.
HemaXellerate I™ is a patient-specific composition of cells that
have previously been demonstrated to repair damaged bone marrow and
stimulate production of blood cells based on previous animal studies.
The company, together with an internationally-renowned group of stem
cell researchers, recently published the scientific basis for the
HemaXellerate I™ product which may be found at http://www.translational-medicine.com/content/pdf/1479-5876-10-231.pdf.
5 day chart
About Bio-Matrix Scientific Group Inc. and Regen BioPharma, Inc.:
Bio-Matrix Scientific Group, Inc. (BMSN) is a biotechnology company
developing regenerative medicine therapies. The Company is focused on
human therapies that address unmet medical needs. Specifically,
Bio-Matrix Scientific Group Inc. is looking to increase the quality of
life through therapies involving stem cell treatments. These treatments
are focused in areas relating to cardiovascular, hematology, oncology
and other indications.
Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group,
Inc. ( PINKSHEETS : BMSN ), is a biotechnology company focused on
identifying undervalued regenerative medicine patents in the stem cell
space and rapidly advancing these technologies through pre-clinical and
Phase I/ II clinical trials. To follow our development, visit us at www.regenbiopharma.com.
OTC Markets
http://www.otcmarkets.com
More info on BMSN: http://www.otcmarkets.com/stock/BMSN/quote
As always, investors need to be aware of risks of investing in microcap OTC stocks.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector,
featuring stock news, commentary and trading alerts in leading sectors
including biotech, tech, mining, energy, water, renewable energy,
beverage stocks and more .
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member and access our 14 online
stock directories 24/7 - water, renewable energy, mining stocks and
more…
http://www.investorideas.com/membership/
Disclaimer/ Disclosure :
The Investorideas.com is a third party publisher of news and research
Our sites do not make recommendations, but offer information portals to
research news, articles, stock lists and recent research. Nothing on our
sites should be construed as an offer or solicitation to buy or sell
products or securities. This site is currently compensated by featured
companies, news submissions and online advertising. Disclosure:
Investorideas.com is long BMSN but has not been compensated for this
report.
BC Residents and Investor Disclaimer : Effective September 15 2008 -
all BC investors should review all OTC and Pink sheet listed companies
for adherence in new disclosure filings and filing appropriate documents
with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com
No comments:
Post a Comment